Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

A University of California, San Diego School of Medicine researcher says she has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment to evaluate possible treatments. The novel cell line, described in the July 16 issue of PLoS ONE, might allow pharmaceutical companies to effectively test new drug candidates or possible vaccines for the HCV infection, which afflicts about 170 million people worldwide. Currently, there is no animal model that is effective for testing such therapies, according to the PLoS ONE paper.

During this week's podcast, Dr. Martina Buck discusses the key components of her HCV infection model system and describes the unique aspects of her tissue culture system. She explains how her system differs from other cell cultures used to study HCV and further explores the paths pharmaceutical companies can follow to take advantage of her new cell line.

Dr. Buck also talks about future plans to take her research project to the next stage.

Martina Buck, Ph.D. is an Assistant Adjunct Professor or Medicine in the Tumor Growth, Invasion & Metastasis Program. Her research is focused on hepatitus C and the signal transuction pathways leading to hepatocellular carcinomas.

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »